The Drug Pricing Machine and Why Patients Keep Paying More

The Drug Pricing Machine analyzes how prescription costs are shaped by pharmacy benefit managers (PBMs), which control about 80% of the U.S. drug market through formularies and rebates tied to list prices. The article notes that rebates often reward higher-priced drugs, contributing to higher costs for patients, and highlights insulin as a case cited by the FTC in 2024. It also notes that the three largest PBMs—CVS Caremark, Express Scripts, and Optum Rx—have faced scrutiny for markup practices and for generating hundreds of millions in revenue above estimated acquisition costs through affiliated pharmacies between 2017 and 2022. The piece argues for greater transparency and reform to realign incentives. Observers say PBMs’ gatekeeper role shapes which drugs are covered and how savings reach patients. Critics point to rebate structures tied to list prices, potential conflicts in vertical integration, and incentives to favor certain manufacturers or pharmacies. The article references a Hunterbox Media investigation into PBM affiliates that raised questions about their limited public visibility and outsized profits. The overall narrative emphasizes that the current system can drive higher medication costs and calls for policy changes to ensure affordability and fair competition in the drug-supply chain.